Loading…
Zhuhai-based pharmaceutical group making generics, diagnostic reagents and biologic/vaccine products.
Zhuhai-based pharmaceutical group making generics, diagnostic reagents and biologic/vaccine products.
Sells medicines and diagnostic kits to Chinese hospitals and labs, where government drug-purchasing rules press prices on older generics and test kits sell on lab volume. Joincare Pharmaceutical, a listed Chinese drug group, is the controlling shareholder. The same company also trades in Hong Kong as 1513.HK.
Moat: narrow (scale, regulatory licence). Broad, diversified drug and diagnostics portfolio built over decades.
Headquarters: Zhuhai, China · Employees: 8,878
Size Livzon Pharmaceutical (000513.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.71B, the 696th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥31.35 on 6 Nov 2026.
Performance Over six months the shares fell 4.0%, against +2.0% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue fell 13.7% over the last twelve months (peer median +6.7%); the operating margin is 19.2% (peer median 15.7%).
Valuation It trades at 16.9× forward earnings against a peer median of 21.5× (6th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.1 points above its cost of capital (5.0% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥10.2B | CN¥11.9B | CN¥11.7B | CN¥12.3B | CN¥12.5B |
| Revenue growth | — | +2% | -5% | -2% | — |
| Gross profit | CN¥6.62B | CN¥7.63B | CN¥7.45B | CN¥7.40B | CN¥7.75B |
| EBITDA | n/a | CN¥3.18B | CN¥3.18B | CN¥2.79B | CN¥2.60B |
| Net income | CN¥1.56B | CN¥2.02B | CN¥2.06B | CN¥1.95B | CN¥1.91B |
| Free cash flow | CN¥2.77B | CN¥2.60B | CN¥2.42B | CN¥2.57B | CN¥1.96B |
| Capital expenditure | CN¥412M | CN¥574M | CN¥570M | CN¥820M | CN¥940M |
| Total debt | CN¥4.20B | CN¥3.85B | CN¥4.95B | CN¥5.04B | CN¥4.63B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Livzon Pharmaceutical 000513.SZ | $3.71B | -4% | -14% | 19% | 16.9× | -9.8% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | $5.18B | -39% | +14% | 11% | 41.6× | 15.5% |
| Humanwell Healthcare (Group) 600079.SS | $4.71B | +3% | -3% | 16% | 13.4× | -6.8% |
| Huadong Medicine 000963.SZ | $7.29B | -17% | +2% | 9% | 14.0× | -2.7% |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | $8.70B | -5% | +8% | 6% | 17.0× | 4.1% |
| Cspc Pharma 1093.HK | $12.4B | +5% | +25% | 28% | 9.3× | -10.3% |
| Hualan Biological Engineering 002007.SZ | $3.37B | -15% | -11% | 17% | 25.5× | 16.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000513.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.9% | +5.2% | 10th highest of 21 |
| 6-month return | -4.0% | +2.0% | 10th lowest of 20 |
| Distance from 52-week high | -17.2% | -26.6% | 7th highest of 21 |
| Revenue growth (TTM) | -13.7% | +6.7% | 3rd lowest of 19 |
| Operating margin | 19.2% | 15.7% | 6th highest of 17 |
| Forward P/E | 16.9× | 21.5× | 6th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | -9.8% | 1.1% | 2nd least demanding of 15 |
| Growth delivered (Del g) | +2.7% | +9.2% | 3rd lowest of 15 |
| Hurdle (Req g minus delivered) | -12.5 pp | -11.2 pp | 7th least demanding of 15 |
| ROIC minus cost of capital | +10.1 pp | +6.0 pp | 6th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Livzon Pharmaceutical 000513.SZ | China | $3.71B | -4% | -14% | 19% | 16.9× | -9.8% | +2.7% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 25.1× | 6.3% | +4.5% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 6.0× | -5.3% | +7.8% |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 21.5× | 16.7% | +19.4% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 4.0× | -4.5% | -1.0% |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 14.3× | -2.8% | +10.6% |
| Xenon Pharmaceuticals XENE | United States | $3.79B | +4% | -100% | n/a | n/a | n/a | n/a |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 43.4× | 20.5% | +98.4% |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 15.6× | -5.2% | +3.2% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% | +5.9% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 22.3× | 1.5% | +12.1% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.47B | +2% | +3% | 19% | 19.6× | -2.2% | +12.0% |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 32.9× | 0.7% | +192.5% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 17.8× | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.42B | -17% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.41B | -37% | +33% | 12% | 23.8× | 15.2% | +61.4% |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 38.6× | 20.2% | +6.2% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.05B | +6% | -4% | 32% | 14.9× | -11.5% | +0.3% |
| Shanghai Junshi Biosciences 688180.SS | China | $4.06B | -24% | +29% | -15% | n/a | n/a | n/a |